Literature DB >> 26003479

Genomic Copy Number Signatures Uncovered a Genetically Distinct Group from Adenocarcinoma and Squamous Cell Carcinoma in Non-Small Cell Lung Cancer.

Eunjung Lee1, Ji Wook Moon2, Xianfu Wang3, Chungyeul Kim4, Shibo Li3, Bong Kyung Shin1, Wonkyung Jung4, Hyun Koo Kim5, Han Kyeom Kim6, Ji-Yun Lee7.   

Abstract

Adenocarcinoma (AC) and squamous cell carcinoma (SCC) of non-small cell lung carcinoma (NSCLC) have different clinical presentations, morphologies, treatments, and prognoses. Recent studies suggested that fundamental genetic alterations related to carcinogenesis of each tumor type may be different. In this study, we investigated the genomic alterations of 47 primary NSCLC samples (22 ACs and 25 SCCs) as well as the corresponding normal tissue using array comparative genomic hybridization. Frequent copy number alterations (CNAs), which were identified in more than 68% of all of the cases, were evaluated in each subtype (SCC and AC), and a CNA signature was established. Among these CNAs, 37 genes from the SCCs and 15 genes from the ACs were located in a region of gain, and 4 genes from the SCCs and 13 genes from the ACs were located in a region of loss. The most frequent gain was located on 3q26-29 including the gene TP63 in SCCs and 7q11.23 and 7q36.3 in ACs. Moreover, we identified 3 genetically distinct groups (group I [16 SCC] with CNA signature of SCC; group II [7 SCC + 8 AC], which has a genetically distinctive CNA signature from SCC and AC; and group III [2 SCC + 14 AC] with CNA signature of AC) by gene clustering extracted from CNAs, which are associated with a prognosis. The present study contributed to the molecular characterization of AC and SCC of NSCLC and showed a subtype of tumor that has a unique genetic CNA signature. However, further study about the significance of these 3 distinct groups and their usefulness as a diagnostic marker of identified CNAs is necessary.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Array CGH; Copy number changes; NSCLC; Squamous cell carcinoma; TP63

Mesh:

Year:  2015        PMID: 26003479     DOI: 10.1016/j.humpath.2015.04.009

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  Prognostic Impact of EGFR Amplification and Visceral Pleural Invasion in Early Stage Pulmonary Squamous Cell Carcinomas Patients after Surgical Resection of Primary Tumor.

Authors:  Luís Miguel Chinchilla-Tábora; José María Sayagués; Idalia González-Morais; Marta Rodríguez; María Dolores Ludeña
Journal:  Cancers (Basel)       Date:  2022-04-27       Impact factor: 6.575

2.  Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model.

Authors:  Jessie R Nedrow; Anders Josefsson; Sunju Park; Tom Bäck; Robert F Hobbs; Cory Brayton; Frank Bruchertseifer; Alfred Morgenstern; George Sgouros
Journal:  EJNMMI Res       Date:  2017-07-18       Impact factor: 3.138

3.  Stratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysis.

Authors:  H-J Thiesen; F Steinbeck; M Maruschke; D Koczan; B Ziems; O W Hakenberg
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

4.  Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer.

Authors:  Federico Rotolo; Chang-Qi Zhu; Elisabeth Brambilla; Stephen L Graziano; Ken Olaussen; Thierry Le-Chevalier; Jean-Pierre Pignon; Robert Kratzke; Jean-Charles Soria; Frances A Shepherd; Lesley Seymour; Stefan Michiels; Ming-Sound Tsao
Journal:  Transl Lung Cancer Res       Date:  2018-06

5.  A long non-coding RNA LNBC3 facilitates non-small cell lung cancer progression by stabilizing BCL6.

Authors:  Jian Shen; Jun Ma; Jianghong Li; Xin Wang; Yi Wang; Jie Ma
Journal:  J Clin Lab Anal       Date:  2019-11-19       Impact factor: 2.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.